research Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
Search
forResearch
5 / 857 results 
research THE UNMET NEEDS OF LUPUS PATIENTS: CREATING VISIBILITY AND SUPPORTING PATIENTS AND FAMILIES IN THEIR JOURNEY
Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
Cancer survivors need better skin care to improve their quality of life.
research Alopecia Areata: Unseen Burdens and Unmet Needs – Comment on ‘The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy’
Alopecia areata causes significant emotional distress, requiring treatments that focus on mental health and social support, not just hair regrowth.
Community Join
5 / 11 resultscommunity Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs
The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.
community European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
community How many years can we expect PP405 to be on the market
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
Clinics
1 / 7 results
Learn
— no results
Experts
— no results